Literature DB >> 2910268

Gentamicin toxicity in the primate retina.

B P Conway1, C A Tabatabay, P A Campochiaro, D J D'Amico, L A Hanninen, K R Kenyon.   

Abstract

To study the toxic effect of aminoglycoside antibiotics in the primate retina, gentamicin sulfate was injected into the center of the vitreous cavity of Cebus navrigatus monkeys. At a dose of 1000 to 3000 microgram, a picture consistent with apparent macular infarction appeared on fundus examination and fluorescein angiography by three days and gradually faded by 21 days. While light and electron microscopic examination of the retina showed no primary vascular lesions, striking damage to the inner retinal layers, mainly the nerve fiber layer, ganglion cell layer, and the inner plexiform and nuclear layer, was seen. Less severe effects in the outer retinal layers and the retinal pigment epithelium occurred. These observations suggest that the neurotoxic effect of intravitreal gentamicin was sufficient to cause a complete shutdown of the regional blood flow, perhaps by the mechanism of granulocytic plugging of the capillary bed. Although this toxic effect occurred at doses considerably in excess of what has been recommended for clinical use in humans, the "safe" dose of intravitreal gentamicin, nevertheless, remains to be established unequivocally.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2910268     DOI: 10.1001/archopht.1989.01070010109037

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  14 in total

1.  Intravitreal antibiotic therapy with vancomycin and aminoglycoside: examination of the retinal toxicity of repetitive injections after vitreous and lens surgery.

Authors:  B S Oum; D J D'Amico; H W Kwak; K W Wong
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1992       Impact factor: 3.117

Review 2.  Current approach to postoperative endophthalmitis.

Authors:  G Sunaric-Mégevand; C J Pournaras
Journal:  Br J Ophthalmol       Date:  1997-11       Impact factor: 4.638

3.  Toxicity and clearance of intravitreal cefotetan.

Authors:  W Philipp; K Schmid; H J Steiner; B Pümpel; F Allerberger; H P Aichberger; W Mayer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1990       Impact factor: 3.117

Review 4.  Factors affecting the efficacy of antibiotics in the treatment of experimental postoperative endophthalmitis.

Authors:  G A Stern
Journal:  Trans Am Ophthalmol Soc       Date:  1993

5.  Emerging Worldwide Antimicrobial Resistance, Antibiotic Stewardship and Alternative Intravitreal Agents for the Treatment of Endophthalmitis.

Authors:  Nidhi Relhan; Avinash Pathengay; Stephen G Schwartz; Harry W Flynn
Journal:  Retina       Date:  2017-05       Impact factor: 4.256

Review 6.  Modeling intraocular bacterial infections.

Authors:  Roger A Astley; Phillip S Coburn; Salai Madhumathi Parkunan; Michelle C Callegan
Journal:  Prog Retin Eye Res       Date:  2016-05-03       Impact factor: 21.198

7.  Antibiotics Reduce Retinal Cell Survival In Vitro.

Authors:  Amy E Lindsey; Ellen Townes-Anderson
Journal:  Neurotox Res       Date:  2017-11-02       Impact factor: 3.911

8.  Clinical presentation, treatment, and genetic and histopathological analysis of juvenile cataracts and secondary glaucoma in a rhesus macaque (Macaca mulatta).

Authors:  M Isabel Casanova; Rui Chen; Laura M Garzel; Katherine J Olstad; Soohyun Kim; Ronald Alan Harris; Yumei Li; Muthuswamy Raveendran; Qingnan Liang; Jun Wang; Glenn Yiu; John Timothy Stout; Jeffrey A Roberts; Jeffrey Rogers; Ala Moshiri; Sara M Thomasy
Journal:  J Med Primatol       Date:  2021-12-12       Impact factor: 0.667

9.  Antimicrobial pharmacokinetics in endophthalmitis treatment: studies of ceftazidime.

Authors:  T A Meredith
Journal:  Trans Am Ophthalmol Soc       Date:  1993

10.  Periocular ulcerative dermatitis associated with gentamicin ointment prophylaxis in newborns.

Authors:  Gil Binenbaum; Christie J Bruno; Brian J Forbes; MaryAnn Snyder; Thomas J Mollen; Barbara Schmidt; Iyalla Peterside
Journal:  J Pediatr       Date:  2010-02       Impact factor: 4.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.